Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin

Uehara,Hisanori; Takahashi,Tetsuyuki; Izumi,Keisuke

doi:10.3892/ijo.2013.1954

Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin

Authors:
- Hisanori Uehara
- Tetsuyuki Takahashi
- Keisuke Izumi
View Affiliations

Affiliations: Department of Molecular and Environmental Pathology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima-shi, Tokushima 770-8503, Japan
Published online on: May 24, 2013 https://doi.org/10.3892/ijo.2013.1954
Pages: 365-374
Copyright: © Uehara et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

New drugs that inhibit the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL)/RANK pathway have demonstrated efficacy for the treatment of bone metastasis. Toxicities induced by these drugs, however, including osteonecrosis of the jaw and hypocalcemia, may adversely affect therapy. The aim of this study was to identify additional therapeutic targets that can be combined with OPG/RANKL/RANK pathway inhibition in the treatment of prostate cancer bone metastasis. We established a stable transfectant that produces high levels of OPG mRNA and protein from PC-3 human prostate cancer cells (PC3-OPG). The culture medium of PC3-OPG cells significantly inhibited the differentiation of mouse monocytes into mature osteoclasts. Furthermore, when PC3-OPG cells were injected into the bones of nude mice, bone destruction and tumor-induced osteoclast formation were reduced. Injection into bone of the mixtures containing equal amounts of green fluorescent protein (GFP)-expressing PC-3 cells (PC3-GFP) and PC3-OPG cells also reduced bone destruction, compared to the control mixture. PC3-GFP cells were subsequently isolated from bone tumors and used for microarray analysis to assess changes in gene expression following osteolytic tumor growth inhibition by OPG. We selected the top 10 upregulated genes based on results from microarrays and confirmed mRNA expression of each gene by RT-PCR. The expression patterns of retinol-binding protein 4 (RBP4) and placenta-specific 8 (PLAC8) were consistent with microarray results. Expression of these genes was also increased in the bone tumors of PC3-GFP/PC3-OPG-injected mice. Knockdown of both RBP4 and PLAC8 by siRNA inhibited the growth of PC-3 cells in vitro. Thus, RBP4 and PLAC8 may become new therapeutic targets for prostate cancer bone metastasis, in combination with OPG/RANKL/RANK pathway inhibition.

View Figures

View References

1.	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2.	Bubendorf L, Schopfer A, Wagner U, et al: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Brown JE, Cook RJ, Major P, et al: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumors. J Natl Cancer Inst. 97:59–69. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Roodman GD: Mechanisms of bone metastasis. N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Demers LM: Bone markers in the management of patients with skeletal metastases. Cancer. 97:874–879. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Percival RC, Urwin GH, Harris S, et al: Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 13:41–49. 1987.PubMed/NCBI
7.	Freedland SJ, Richhariya A, Wang H, Chung K and Shore ND: Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology. 80:293–298. 2012. View Article : Google Scholar : PubMed/NCBI
8.	Coleman R, Gnant M, Morgan G and Clezardin P: Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 104:1059–1067. 2012. View Article : Google Scholar : PubMed/NCBI
9.	Mundy GR: Mechanisms of osteolytic bone destruction. Bone. 12(Suppl 1): S1–S6. 1991. View Article : Google Scholar
10.	Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
12.	Bucay N, Sarosi I, Dunstan CR, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260–1268. 1998. View Article : Google Scholar : PubMed/NCBI
13.	Zhang J, Dai J, Qi Y, et al: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235–1244. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Corey E, Brown LG, Kiefer JA, et al: Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 65:1710–1718. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Zhang J, Dai J, Yao Z, Lu Y, Dougall W and Keller ET: Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 63:7883–7890. 2003.PubMed/NCBI
16.	Shipman CM and Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63:912–916. 2003.
17.	Holen I, Croucher PI, Hamdy FC and Eaton CL: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62:1619–1623. 2002.PubMed/NCBI
18.	McGonigle JS, Giachelli CM and Scatena M: Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 12:35–46. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Peddi P, Lopez-Olivo MA, Pratt GF and Suarez-Almazor ME: Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 39:97–104. 2013. View Article : Google Scholar : PubMed/NCBI
20.	Brown-Glaberman U and Stopeck AT: Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics. 6:89–99. 2012.PubMed/NCBI
21.	Uehara H, Kim SJ, Karashima T, et al: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 95:458–470. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Uemura H, Yanagisawa M, Ikeda I, et al: Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial. Int J Clin Oncol. Apr 11–2012, (Epub ahead of print).
23.	Smith MR, Saad F, Coleman R, et al: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 379:39–46. 2012. View Article : Google Scholar
24.	Smith MR, Egerdie B, Hernandez Toriz N, et al: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 361:745–755. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Fizazi K, Lipton A, Mariette X, et al: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 27:1564–1571. 2009. View Article : Google Scholar
26.	Lipton A, Steger GG, Figueroa J, et al: Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 25:4431–4437. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Lipton A, Fizazi K, Stopeck AT, et al: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 48:3082–3092. 2012. View Article : Google Scholar : PubMed/NCBI
28.	Ford JA, Jones R, Elders A, et al: Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer. 49:416–430. 2013. View Article : Google Scholar : PubMed/NCBI
29.	Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28:5132–5139. 2010. View Article : Google Scholar
30.	Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45. 2001. View Article : Google Scholar : PubMed/NCBI
31.	Ting HJ, Hsu J, Bao BY and Lee YF: Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. Cancer Lett. 247:122–129. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Bao BY, Hu YC, Ting HJ and Lee YF: Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene. 23:3350–3360. 2004. View Article : Google Scholar : PubMed/NCBI
33.	Arah IN, Song K, Seth P, Cowan KH and Sinha BK: Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells. Anticancer Res. 18:1845–1849. 1998.PubMed/NCBI
34.	Fisher JL, Thomas-Mudge RJ, Elliott J, et al: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66:3620–3628. 2006. View Article : Google Scholar
35.	Flower DR: The lipocalin protein family: structure and function. Biochem J. 318:1–14. 1996.
36.	Newcomer ME and Ong DE: Plasma retinol binding protein: structure and function of the prototypic lipocalin. Biochim Biophys Acta. 1482:57–64. 2000. View Article : Google Scholar : PubMed/NCBI
37.	Tsutsumi C, Okuno M, Tannous L, et al: Retinoids and retinoid-binding protein expression in rat adipocytes. J Biol Chem. 267:1805–1810. 1992.PubMed/NCBI
38.	Kovacs P, Geyer M, Berndt J, et al: Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot-specific mRNA expression. Diabetes. 56:3095–3100. 2007. View Article : Google Scholar : PubMed/NCBI
39.	Graham TE, Yang Q, Bluher M, et al: Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med. 354:2552–2563. 2006. View Article : Google Scholar : PubMed/NCBI
40.	Yang Q, Graham TE, Mody N, et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 436:356–362. 2005. View Article : Google Scholar : PubMed/NCBI
41.	Abel ED, Peroni O, Kim JK, et al: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 409:729–733. 2001. View Article : Google Scholar : PubMed/NCBI
42.	Abulaizi M, Tomonaga T, Satoh M, et al: The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer. Int J Proteomics. 2011:6287872011. View Article : Google Scholar : PubMed/NCBI
43.	Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR and Herndon JE II: Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 25:5578–5583. 2007. View Article : Google Scholar : PubMed/NCBI
44.	Mourtada-Maarabouni M, Watson D, Munir M, Farzaneh F and Williams GT: Apoptosis suppression by candidate oncogene PLAC8 is reversed in other cell types. Curr Cancer Drug Targets. 13:80–91. 2012. View Article : Google Scholar : PubMed/NCBI
45.	Li Y, Rogulski K, Zhou Q, Sims PJ and Prochownik EV: The negative c-Myc target onzin affects proliferation and apoptosis via its obligate interaction with phospholipid scramblase 1. Mol Cell Biol. 26:3401–3413. 2006. View Article : Google Scholar : PubMed/NCBI
46.	Rogulski K, Li Y, Rothermund K, et al: Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway. Oncogene. 24:7524–7541. 2005. View Article : Google Scholar : PubMed/NCBI